Literature DB >> 6313379

Volume of distribution terms for a drug (ceftriaxone) exhibiting concentration-dependent protein binding. I. Theoretical considerations.

P J McNamara, M Gibaldi, K Stoeckel.   

Abstract

We have theoretically examined the influence of plasma protein binding (specifically the fraction unbound, fp) on the pharmacokinetic parameters following rapid injection of a drug undergoing concentration-dependent binding. Particular emphasis was placed on the apparent volume of distribution terms based on both total and unbound drug concentrations. Computer simulations were performed to establish the validity and utility of such relationships. The following observations were made: a) distributional parameters based on total drug (both V beta and the model-independent VSS) were inaccurate/invalid; b) V beta based on unbound drug was misleading; c) the model-independent VSS for unbound drug accurately predicted the steady state situation. Furthermore, two new terms (-fp and V-TSS) were introduced which provide additional insight concerning the disposition of this type of drug. The -fp is the area-weighted average fraction unbound in the plasma and V-TSS is the corrected steady state distribution term for total drug levels. The present study indicates that useful distributional and clearance terms can be calculated for this type of drug, provided that the time course of unbound drug as well as total drug can be followed. Moreover, guidelines for their extrapolation to steady state conditions and their correct interpretations are discussed.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6313379     DOI: 10.1007/bf01037955

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  17 in total

1.  Commentary: a physiological approach to hepatic drug clearance.

Authors:  G R Wilkinson; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

2.  The disposition of propranolol. 3. Decreased half-life and volume of distribution as a result of plasma binding in man, monkey, dog and rat.

Authors:  G H Evans; A S Nies; D G Shand
Journal:  J Pharmacol Exp Ther       Date:  1973-07       Impact factor: 4.030

3.  Numerical solution of nonlinear pharmacokinetic equations: effects of plasma protein binding on drug distribution and elimination.

Authors:  J J Coffey; F J Bullock; P T Schoenemann
Journal:  J Pharm Sci       Date:  1971-11       Impact factor: 3.534

4.  Effect of saturable binding on the pharmacokinetics of drugs: a simulation.

Authors:  S Oie; T W Guentert; T N Tozer
Journal:  J Pharm Pharmacol       Date:  1980-07       Impact factor: 3.765

5.  Accumulation kinetics of drugs with nonlinear plasma protein and tissue binding characteristics.

Authors:  P J McNamara; J T Slattery; M Gibaldi; G Levy
Journal:  J Pharmacokinet Biopharm       Date:  1979-08

6.  Pharmacokinetics of ceftriaxone following intravenous administration of a 3 g dose.

Authors:  P J McNamara; K Stoeckel; W H Ziegler
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

7.  Fraction unbound in interstitial fluid.

Authors:  P J McNamara; M Gibaldi; K Stoeckel
Journal:  J Pharm Sci       Date:  1983-07       Impact factor: 3.534

8.  Effect of plasma protein and tissue binding on the biologic half-life of drugs.

Authors:  M Gibaldi; G Levy; P J McNamara
Journal:  Clin Pharmacol Ther       Date:  1978-07       Impact factor: 6.875

9.  Pharmacokinetic models regarding protein binding of drugs.

Authors:  E Krüger-Thiemer; W Diller; P Bünger
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1965

10.  Determination of common parameters fo iodothyronine metabolism and distribution in man by noncompartmental analysis.

Authors:  J H Oppenheimer; H L Schwartz; M I Surks
Journal:  J Clin Endocrinol Metab       Date:  1975-08       Impact factor: 5.958

View more
  20 in total

1.  Clearance of ceftriaxone in critical care patients with acute renal failure.

Authors:  G Heinemeyer; J Link; W Weber; V Meschede; I Roots
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

Review 2.  Nonlinear Protein Binding: Not What You Think.

Authors:  Amelia N Deitchman; Ravi Shankar Prasad Singh; Hartmut Derendorf
Journal:  J Pharm Sci       Date:  2018-04-04       Impact factor: 3.534

3.  Volumes of distribution and mean residence time of drugs with linear tissue distribution and binding and nonlinear protein binding.

Authors:  H Cheng; W R Gillespie
Journal:  J Pharmacokinet Biopharm       Date:  1996-08

4.  Effect of protein binding of daptomycin on MIC and antibacterial activity.

Authors:  B L Lee; M Sachdeva; H F Chambers
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

5.  Effect of saturable serum protein binding on the pharmacokinetics of unbound cefonicid in humans.

Authors:  M N Dudley; W C Shyu; C H Nightingale; R Quintiliani
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

6.  Pharmacokinetic effects of altered plasma protein binding of drugs in renal disease.

Authors:  F Keller; M Maiga; H H Neumayer; H Lode; A Distler
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1984 Jul-Sep       Impact factor: 2.441

7.  Volume of distribution terms for a drug (ceftriaxone) exhibiting concentration-dependent protein binding. II. Physiological significance.

Authors:  P J McNamara; M Gibaldi; K Stoeckel
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 8.  Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  D M Richards; R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-06       Impact factor: 9.546

9.  Characteristics of ceftriaxone binding to immunoglobulin G and potential clinical significance.

Authors:  H Sun; M S Chow; E G Maderazo
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

10.  Biliary excretion and pharmacokinetics of ceftriaxone after cholecystectomy.

Authors:  W L Hayton; R Schandlik; K Stoeckel
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.